New Lyme Disease Test Submitted for FDA Approval by DiaSorin

new lyme disease test360 Dx published announcement 01.25.2024, that the diagnostic laboratory research company, DiaSorin, has submitted a new test for the early identification of Lyme disease, for approval by US Food and Drug Administration (FDA).The Liaison LymeDetect test, an immunoassay, was developed in partnership with Qiagen.

This test is powered by DiaSorin’s Liaison analyzers combined with Qiagen’s QuantiFeron interferon-gamma release assay (IGRA) technology. The test incorporates three chemiluminescent assays for detection of IgG, IgM, and T-cell mediated responses to Borrelia burgdorferi infections, and is to be used in conjunction with clinical signs and symptoms of Lyme disease.

For More Information: 

Read the 360 Dx article

Read More LDA Articles on Lyme Disease Tests